Profile
Sector:
HealthcareIndustry:
Medical Instruments & SuppliesCountry:
United StatesIPO:
03 May 2010Next earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:48:34 GMTDividend
Analysts recommendations
Institutional Ownership
POAI Latest News
Predictive Oncology's organ-specific in vitro models are designed to better mimic the physiological environment of human tissue
Study successfully demonstrated Predictive's ability to build AI multi-omic machine learning models to predict survival outcomes among ovarian cancer patients better than clinical data alone Study successfully demonstrated Predictive's ability to build AI multi-omic machine learning models to predict survival outcomes among ovarian cancer patients better than clinical data alone
Predictive Oncology Inc. (NASDAQ:POAI ) Q3 2023 Earnings Conference Call November 14, 2023 8:30 AM ET Company Participants Glenn Garmont - IR Raymond Vennare - CEO and Chairman Josh Blacher - CFO Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Predictive Oncology Q3 2023 Earnings Conference Call.
Predictive Oncology Inc. (NASDAQ:POAI) listed a number of recent milestones with the release of its third-quarter results, which also revealed a significant 22% reduction in its net loss. Chairman and CEO Raymond Vennare highlighted the delivery of successful results from its first campaign with Cancer Research Horizons, a subsidiary of the largest independent funder of cancer research in the world.
Predictive Oncology Inc announced that it has completed a multi-year study with UPMC Magee-Womens Hospital in Pittsburgh. The science-driven company said the objective of the study was to evaluate the use of AI to build multi-omic machine learning (ML) models and test if these models can learn associations between the datasets and ovarian cancer patient short- and long-term survival.
Predictive Oncology, Inc. (NASDAQ:POAI ) Q2 2023 Earnings Conference Call August 10, 2023 5:30 PM ET Company Participants Glenn Garmont - Managing Director at LifeSci Partners Raymond Vennare - Chief Executive Officer and Chairman of the Board Bob Myers - Chief Financial Officer Pamela Bush - Chief Business Officer Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Predictive Oncology Q2 2023 Earnings Conference Call.
Predictive Oncology reported its second-quarter financial results after the bell Thursday, including a significantly narrower loss than the same quarter of 2022. The drug development company reported a loss of $0.98 per share, compared to $2.89 in the year-ago quarter.
Predictive Oncology Inc. (NASDAQ:POAI) announced that it has moved its corporate headquarters to its main laboratory facility in Pittsburgh, Pennsylvania. The science-driven company said the logistical initiative further strengthens its commitment to scientific discovery and growth potential.
Predictive Oncology Inc. (NASDAQ:POAI) has announced the addition of biopharmaceutical finance industry veteran Andrew Einhorn to its business advisory board. Einhorn is the chief financial officer at Danforth Advisors, where he helps build up life science companies using institutional knowledge and provides financial advisory services to public and privately held companies.
Predictive Oncology Inc. (NASDAQ:POAI) has announced the appointment of Dr Bernard Harris Jr to its newly-formed Business Advisory Board (BAB). The company said Harris, who previously worked at NASA, serves as CEO and managing partner of Vesalius Ventures, Inc, a venture capital firm that supports and invests in early-to-mid-stage healthcare companies.
What type of business is Predictive Oncology?
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
What sector is Predictive Oncology in?
Predictive Oncology is in the Healthcare sector
What industry is Predictive Oncology in?
Predictive Oncology is in the Medical Instruments & Supplies industry
What country is Predictive Oncology from?
Predictive Oncology is headquartered in United States
When did Predictive Oncology go public?
Predictive Oncology initial public offering (IPO) was on 03 May 2010
What is Predictive Oncology website?
https://www.predictive-oncology.com
Is Predictive Oncology in the S&P 500?
No, Predictive Oncology is not included in the S&P 500 index
Is Predictive Oncology in the NASDAQ 100?
No, Predictive Oncology is not included in the NASDAQ 100 index
Is Predictive Oncology in the Dow Jones?
No, Predictive Oncology is not included in the Dow Jones index
When does Predictive Oncology report earnings?
The next expected earnings date for Predictive Oncology is 09 August 2024